Proactive Investors - Run By Investors For Investors

ImmunoPrecise says ModiQuest managing director leaving to take CEO role

Raats founded ModiQuest Research in 2005 and served as its CEO
A photo from a lab
Netherlands-based ModiQuest was acquired by ImmunoPrecise last year

ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) said Friday that Jos Raats has resigned from his position as managing director of its ModiQuest Research BV subsidiary to pursue duties as CEO of Absano BV.

Raats founded Netherlands-based ModiQuest Research in 2005 and served as its CEO. ImmunoPrecise acquired the company last year.

"I want to thank Jos for his valuable service and leadership," ImmunoPrecise CEO Jennifer Bath said in a statement. "He was instrumental in integration of ModiQuest Research into the IPA family of companies.”

READ: Immunoprecise shares now eligible for electronic clearing and settlement in the US

Shares of Victoria, British Columbia-based Immunoprecise climbed C$0.01 to C$0.81 in Friday’s Canadian trading. They gained US$0.01 to US$0.60 on the OTC Markets.

Absano is developing antibodies for therapeutic and diagnostic applications in the field of cancer, autoimmunity and infection. It’s working with TACPA BV, a clinical-stage company focusing on a Phase 1 anti-inflammatory antibody candidate directed at multiple diseases that was developed using ModiQuest's antibody technologies.

In addition, ImmunoPrecise said Debby Kruijsen is the new general manager of ModiQuest Research. In 2012, she joined ModiQuest Research as a scientist supervising hybridoma antibody discovery projects. A year later, she became responsible for contract research projects.

In February, ImmunoPrecise announced that its common shares were now eligible for electronic clearing and settlement through the Depository Trust Co in the US.

Contact Dennis Fitzgerald at [email protected]

View full IPA profile View Profile

ImmunoPrecise Antibodies Ltd Timeline

Related Articles

1550850611_CancerHeadline.jpg
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
cancer
February 25 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use